Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab

Fig. 3

Associations of KIR2DL2 and KIR3DL1 and their ligand status with clinical outcomes. Kaplan-Meier curves for TTRF (non-biological events censored) (a) and for duration of response (b) compare those treated with maintenance rituximab and Group 1 (KIR2DL2+/C1+/KIR3DL1+/Bw4+) (Line 1: solid-black line), those treated with maintenance rituximab and Group 2 (not KIR2DL2+/C1+/KIR3DL1+/Bw4+) (Line 2: dashed-black line), those treated with non-maintenance rituximab and Group 1 (Line 3: solid-red line) and those treated with non-maintenance rituximab and Group 2 (Line 4: dashed-red line). c displays box-plots for percent tumor shrinkage for the four groups above (p-value not shown if p > 0.1). Outlying values are shown as filled circles outside the horizontal lines. (“*” indicates p < 0.05; “***” indicates p < 0.001)

Back to article page